How much does one injection of margetuximab cost and can it be reimbursed by medical insurance?

Margetuximab (Margetuximab-cmkb) is a new type of HER2 targeted therapy drug, mainly used for the treatment of patients with HER2 positive advanced breast cancer. The drug was developed by MacroGenics and has been approved for marketing in Europe, the United States, Japan and other countries in recent years. With the gradual diversification of anti-HER2 drugs, margetuximab has shown a better immune effect than trastuzumab due to its unique Fc engineering modification, which has gradually attracted widespread attention in the medical community. This is a potential option for patients looking for an alternative to trastuzumab.

Currently, margetuximab has been approved for marketing in China, but due to its short time on the market, it has not yet been included in the national medical insurance directory. Therefore, patients using this drug in the country cannot be reimbursed through medical insurance for the time being. In other words, the current full cost of using margetuximab still needs to be paid out of pocket. It is recommended that patients fully communicate with their attending doctors and hospital pharmacies before use to ensure accurate pricing and medication protection information. In addition, the medical insurance catalog is updated periodically. If the clinical demand for this drug increases in the future, it may be included in the medical insurance coverage.

From a price point of view, the price of margetuximab is relatively high. In overseas markets, including Europe and Japan, the common specifications of the original version of margituximab are 250mg/10ml*1bottles/boxes, and the price is about more than 30,000 yuan. It should be noted that this price may vary due to exchange rate fluctuations, import channels and regional differences. In addition, there are currently no generic versions of this drug on the market, so patients need to budget in advance or seek support from public assistance projects in terms of financial burden.

In general, as an innovative HER2 targeted drug, margituximab has demonstrated unique advantages in clinical application. However, the reality of high price, lack of reimbursement by medical insurance and lack of generic versions means that it will take some time for its large-scale promotion in China. It is recommended that patients fully understand its indications, efficacy data and cost before choosing this drug for treatment, make scientific decisions based on their own condition and economic conditions, and consult regular medical institutions for more medication guidance and financial assistance suggestions.

Reference materials:https://www.drugs.com